SG11201408421TA - Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof - Google Patents
Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereofInfo
- Publication number
- SG11201408421TA SG11201408421TA SG11201408421TA SG11201408421TA SG11201408421TA SG 11201408421T A SG11201408421T A SG 11201408421TA SG 11201408421T A SG11201408421T A SG 11201408421TA SG 11201408421T A SG11201408421T A SG 11201408421TA SG 11201408421T A SG11201408421T A SG 11201408421TA
- Authority
- SG
- Singapore
- Prior art keywords
- aminotetrahydroquinoline
- novel
- carboxylic acids
- carboxylic
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12177284 | 2012-07-20 | ||
EP13167967 | 2013-05-16 | ||
PCT/EP2013/065017 WO2014012934A1 (en) | 2012-07-20 | 2013-07-16 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408421TA true SG11201408421TA (en) | 2015-02-27 |
Family
ID=48914233
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408421TA SG11201408421TA (en) | 2012-07-20 | 2013-07-16 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
SG10201700454PA SG10201700454PA (en) | 2012-07-20 | 2013-07-16 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201700454PA SG10201700454PA (en) | 2012-07-20 | 2013-07-16 | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof |
Country Status (41)
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS55940B1 (en) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
EP2840076B1 (en) * | 2012-04-16 | 2017-10-25 | TOA Eiyo Ltd. | Bicyclic compound |
JP6324956B2 (en) | 2012-07-20 | 2018-05-16 | バイエル・ファルマ・アクティエンゲゼルシャフト | Substituted aminoindane- and aminotetralin carboxylic acids and uses thereof |
DK2875003T3 (en) * | 2012-07-20 | 2017-02-20 | Bayer Pharma AG | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THE USE OF IT |
FR3000065A1 (en) * | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | BICYCLIC COMPOUNDS HAVING ACTIVITY POTENTIATING THE ACTIVITY OF AN ACTIVE ANTIBIOTIC AGAINST MYCOBACTERIA-PHARMACEUTICAL COMPOSITION AND PRODUCT COMPRISING SUCH COMPOUNDS |
RU2749213C2 (en) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Co-crystals of transmembrane conduction regulator modulators in cystic fibrosis |
BR112017023855A2 (en) | 2015-05-06 | 2018-07-17 | Bayer Pharma Aktiengesellschaft | the use of separate sgc stimulants, scg activators and combinations with pde5 inhibitors for the treatment of multiple sclerosis (ssc) concurrent digital (du) ulcers |
HUE052337T2 (en) | 2015-07-23 | 2021-04-28 | Bayer Pharma AG | Stimulators/activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof |
CA3031603A1 (en) | 2016-07-22 | 2018-01-25 | Toa Eiyo Ltd. | Therapeutic agent for glaucoma |
JP7237823B2 (en) | 2016-10-11 | 2023-03-13 | バイエル ファーマ アクチエンゲゼルシャフト | Combinations comprising SGC activators and mineralocorticoid receptor antagonists |
WO2018153899A1 (en) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators |
WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Use of activators and stimulators of sgc comprising a beta2 subunit |
SG11202003641RA (en) | 2017-10-24 | 2020-05-28 | Bayer Ag | Substituted imidazopyridine amides and use thereof |
EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
CN108218770A (en) * | 2018-02-28 | 2018-06-29 | 南京波普生物医药研发有限公司 | The preparation method of the chloro- 7,8- dihydros -6H- quinoline -5- ketone of 2- |
EP3787610A1 (en) | 2018-04-30 | 2021-03-10 | Bayer Aktiengesellschaft | The use of sgc activators and sgc stimulators for the treatment of cognitive impairment |
AU2019269047A1 (en) | 2018-05-15 | 2020-11-26 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
WO2020216669A1 (en) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenyl-substituted imidazopyridine amides and use thereof |
KR20220005556A (en) | 2019-05-07 | 2022-01-13 | 바이엘 악티엔게젤샤프트 | MASP inhibitory compounds and uses thereof |
EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
KR20230012494A (en) | 2020-05-20 | 2023-01-26 | 바이엘 악티엔게젤샤프트 | Butyl (5S)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chloro-4'-(trifluoromethyl)[biphenyl]- Method for producing 4-yl]methoxy}phenyl)ethyl]amino)-5,6,7,8-tetrahydroquinoline-2-carboxylate |
WO2023126436A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
WO2023126438A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
AU2022424376A1 (en) * | 2021-12-29 | 2024-07-04 | Bayer Aktiengesellschaft | Treatment of cardiopulmonary disorders |
WO2023237577A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8004002L (en) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | THERAPEUTICALLY APPLICABLE TETRALIN DERIVATIVES |
IL65501A (en) | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
DE3718317A1 (en) | 1986-12-10 | 1988-06-16 | Bayer Ag | SUBSTITUTED BASIC 2-AMINOTETRALINE |
DE3719924A1 (en) | 1986-12-22 | 1988-06-30 | Bayer Ag | 8-SUBSTITUTED 2-AMINOTETRALINE |
AU654653B2 (en) | 1989-05-31 | 1994-11-17 | Pharmacia & Upjohn Company | Therapeutically useful 2-aminotetralin derivatives |
FR2659853A1 (en) | 1990-03-22 | 1991-09-27 | Midy Spa | Use of 2-aminotetralin derivatives for the preparation of medicaments intended for combating disorders of intestinal motor function |
ATE346598T1 (en) | 1994-01-10 | 2006-12-15 | Teva Pharma | 1-AMINOINDANDERIVATES AND COMPOSITIONS THEREOF |
WO1999062505A2 (en) | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
DE19834044A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | New substituted pyrazole derivatives |
DE19834047A1 (en) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituted pyrazole derivatives |
GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
DE19943635A1 (en) | 1999-09-13 | 2001-03-15 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
AR031176A1 (en) | 2000-11-22 | 2003-09-10 | Bayer Ag | NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE |
DE10109858A1 (en) | 2001-03-01 | 2002-09-05 | Bayer Ag | Novel halogen-substituted aminodicarboxylic acid derivatives |
DE10109861A1 (en) | 2001-03-01 | 2002-09-05 | Bayer Ag | Novel side chain halogenated aminodicarboxylic acid derivatives |
DE10109859A1 (en) | 2001-03-01 | 2002-09-05 | Bayer Ag | Novel aminodicarboxylic acid derivatives |
DE10110749A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituted aminodicarboxylic acid derivatives |
DE10110750A1 (en) | 2001-03-07 | 2002-09-12 | Bayer Ag | Novel aminodicarboxylic acid derivatives with pharmaceutical properties |
DE10220570A1 (en) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamate-substituted pyrazolopyridines |
US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
US7803951B2 (en) | 2005-03-30 | 2010-09-28 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
DE102005047946A1 (en) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases |
DE102005050377A1 (en) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclic compounds and their use |
DE102006031175A1 (en) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Aqueous drug formulation of 4 - [((4-carboxybutyl) - (2 [(4-phenethyl-benzyl) oxy] -phenethyl) amino) methyl] benzoic acid |
WO2009023669A1 (en) | 2007-08-13 | 2009-02-19 | Janssen Pharmaceutica N.V. | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
EA201070339A1 (en) | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | ACTIVATORS OF SOLUBLE GUANYLATZYCLASES |
JP5937353B2 (en) * | 2008-08-19 | 2016-06-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | Cold sensation-menthol receptor antagonist |
DE102010020553A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituted 8-alkoxy-2-aminotetralin derivatives and their use |
DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US20130158028A1 (en) | 2010-06-25 | 2013-06-20 | Bayer Intellectual Property Gmbh | Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes |
CA2804470A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
DE102010043379A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use |
US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
EP2840076B1 (en) * | 2012-04-16 | 2017-10-25 | TOA Eiyo Ltd. | Bicyclic compound |
JP6324956B2 (en) | 2012-07-20 | 2018-05-16 | バイエル・ファルマ・アクティエンゲゼルシャフト | Substituted aminoindane- and aminotetralin carboxylic acids and uses thereof |
DK2875003T3 (en) * | 2012-07-20 | 2017-02-20 | Bayer Pharma AG | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THE USE OF IT |
-
2013
- 2013-07-16 DK DK13744464.2T patent/DK2875003T3/en active
- 2013-07-16 JP JP2015522074A patent/JP6251259B2/en active Active
- 2013-07-16 BR BR112015001211-6A patent/BR112015001211B1/en active IP Right Grant
- 2013-07-16 CA CA2879369A patent/CA2879369C/en active Active
- 2013-07-16 NZ NZ702977A patent/NZ702977A/en unknown
- 2013-07-16 LT LTEP13744464.2T patent/LT2875003T/en unknown
- 2013-07-16 CN CN201380048579.2A patent/CN104822661B/en active Active
- 2013-07-16 RS RS20170110A patent/RS55651B1/en unknown
- 2013-07-16 ME MEP-2017-30A patent/ME02603B/en unknown
- 2013-07-16 WO PCT/EP2013/065017 patent/WO2014012934A1/en active Application Filing
- 2013-07-16 MY MYPI2015000125A patent/MY172994A/en unknown
- 2013-07-16 MX MX2015000739A patent/MX360863B/en active IP Right Grant
- 2013-07-16 SG SG11201408421TA patent/SG11201408421TA/en unknown
- 2013-07-16 ES ES13744464.2T patent/ES2616036T3/en active Active
- 2013-07-16 EA EA201590251A patent/EA028918B9/en not_active IP Right Cessation
- 2013-07-16 PT PT137444642T patent/PT2875003T/en unknown
- 2013-07-16 SI SI201330514A patent/SI2875003T1/en unknown
- 2013-07-16 PL PL13744464T patent/PL2875003T3/en unknown
- 2013-07-16 PE PE2015000049A patent/PE20150350A1/en active IP Right Grant
- 2013-07-16 HU HUE13744464A patent/HUE030540T2/en unknown
- 2013-07-16 AU AU2013292046A patent/AU2013292046C1/en active Active
- 2013-07-16 SG SG10201700454PA patent/SG10201700454PA/en unknown
- 2013-07-16 KR KR1020157001058A patent/KR102137517B1/en active IP Right Grant
- 2013-07-16 EP EP13744464.2A patent/EP2875003B1/en active Active
- 2013-07-18 US US13/945,675 patent/US8981104B2/en active Active
- 2013-07-18 JO JOP/2013/0216A patent/JO3343B1/en active
- 2013-07-18 AR ARP130102566A patent/AR091838A1/en active IP Right Grant
- 2013-07-19 UY UY0001034918A patent/UY34918A/en active IP Right Grant
- 2013-07-19 TW TW102125865A patent/TWI598338B/en active
-
2014
- 2014-12-19 ZA ZA2014/09394A patent/ZA201409394B/en unknown
-
2015
- 2015-01-11 IL IL236616A patent/IL236616B/en active IP Right Grant
- 2015-01-14 PH PH12015500106A patent/PH12015500106A1/en unknown
- 2015-01-15 CO CO15007422A patent/CO7240369A2/en unknown
- 2015-01-16 DO DO2015000012A patent/DOP2015000012A/en unknown
- 2015-01-16 CL CL2015000120A patent/CL2015000120A1/en unknown
- 2015-01-19 TN TNP2015000026A patent/TN2015000026A1/en unknown
- 2015-01-19 EC ECIEPI20151882A patent/ECSP15001882A/en unknown
- 2015-01-20 CR CR20150020A patent/CR20150020A/en unknown
- 2015-01-20 GT GT201500011A patent/GT201500011A/en unknown
- 2015-01-29 US US14/609,122 patent/US9688636B2/en active Active
- 2015-10-13 HK HK15109955.7A patent/HK1209413A1/en unknown
-
2017
- 2017-02-02 HR HRP20170185TT patent/HRP20170185T1/en unknown
- 2017-02-03 CY CY20171100161T patent/CY1118588T1/en unknown
- 2017-05-19 US US15/600,132 patent/US10053428B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209413A1 (en) | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof 5--2- | |
HK1203493A1 (en) | Substituted azabicycles and use thereof | |
HK1199023A1 (en) | Substituted benzothienylpyrrolotriazines and uses thereof | |
HK1202545A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
HK1200822A1 (en) | Substituted dipyridylamines and uses thereof | |
HK1211282A1 (en) | Substituted aminoindane and aminotetralincarboxylic acids and use thereof | |
EP2870170A4 (en) | Novel peptides and use thereof | |
HK1210949A1 (en) | Combinations and uses thereof | |
HK1203198A1 (en) | Substituted phenylimidazopyrazoles and use thereof | |
HK1207301A1 (en) | Substituted benzamides and their uses | |
HK1201270A1 (en) | Tetrazol-5-yl- and triazol-5-yl-aryl compounds and use thereof as herbicides -5---5-- | |
HK1210809A1 (en) | Beta-hexosyl-transferases and uses thereof | |
EP2918600A4 (en) | Novel peptide and use thereof | |
HK1207154A1 (en) | C1q-adiponectin complex and use thereof c1q- | |
AP2015008228A0 (en) | Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof | |
GB201213726D0 (en) | Novel compounds and their use | |
GB201220504D0 (en) | Product and use thereof | |
GB201222541D0 (en) | Kiddibidet and pottibidet | |
IL218974A0 (en) | Conaction bitwen coutch and playels | |
GB201202021D0 (en) | Co-sleeper and breastfeeder |